Leo Pharma boss on newly purchased drug: "It is a very cleverly designed antibody"

Kim Kjøller, research director at Leo Pharma, wants to attack atopic dermatitus from all sides, and the company's new DKK 3.9 billion (USD 569 million) purchase is an addition to that plan.

Kim Kjøller, research director at Leo Pharma. | Photo: Leo Pharma/ PR

On Wednesday, Leo Pharma added another potential weapon to its arsenal of treatments for skin disease atopic dermatitis (eczema), when the company paid DKK 270 million (USD 39 million) and promised DKK 3.6 billion (USD 526 billion) in milestone payments for antibody FB825.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs